XML 55 R24.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2021
Segment Reporting [Abstract] |
Segment Information | Segment Information The Company manages its operations through two operating and reportable segments: Medical and Industrial. These segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s Chief Executive Officer, its Chief Operating Decision Maker (“CODM”), reviews and evaluates the Company’s operations. The CODM allocates resources and evaluates the financial performance of each operating segment. The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Prior period information herein has been conformed to the current reportable segment structure. Description of Segments The Medical segment provides radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world, dosimetry solutions for monitoring the total amount of radiation medical staff members are exposed to over time, radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy, and radionuclide therapy products for nuclear medicine applications such as shielding, product handling, medical imaging furniture, and rehabilitation products. The Industrial segment provides robust, field ready personal radiation detection and identification equipment for defense applications and radiation detection and analysis tools for power plants, labs, and research applications. Nuclear power plant product offerings are used for the full nuclear power plant lifecycle including core detectors and essential measurement devices for new build, maintenance, decontamination and decommission equipment for monitoring and control during fuel dismantling and remote environmental monitoring. The following table summarizes select operating results for each reportable segment. The CODM evaluates operating results and allocates capital resources among segments, in part, based on segment income from operations, which includes revenues of the segment less expenses that are directly related to those revenues, including purchase accounting impacts to revenue and cost of revenues, but excluding certain charges to cost of revenues and selling, general and administrative expenses predominantly related to corporate costs, shared overhead and other non-operational costs related to restructuring activities and costs to achieve operational initiatives, which are included in "Corporate and Other" in the table below. Interest expense, loss on debt extinguishment, foreign currency loss (gain), net, and other expense (income), net, are not allocated to segments.
| Successor |  |  | Predecessor
(in millions) | From October 20, 2021 through December 31, 2021 |  |  | From July 1, 2021 through October 19, 2021 |  | For Year Ended June 30. 2021 |  | For Year Ended June 30. 2020 |  | For Year Ended June 30, 2019
Revenues |  |  |  |  |  |  |  |  |  |
Medical | $ | 49.2 |  |  |  | $ | 60.3 |  |  | $ | 155.7 |  |  | $ | 62.6 |  |  | $ | 42.9 |
Industrial | 104.9 |  |  |  | 107.7 |  |  | 455.9 |  |  | 415.6 |  |  | 397.2 |
Consolidated Revenues | $ | 154.1 |  |  |  | $ | 168.0 |  |  | $ | 611.6 |  |  | $ | 478.2 |  |  | $ | 440.1 |
Segment Income from Operations |  |  |  |  |  |  |  |  |  |
Medical | $ | (4.3) |  |  |  | $ | 0.7 |  |  | $ | 6.0 |  |  | $ | 13.9 |  |  | $ | 10.2 |
Industrial | 1.1 |  |  |  | 11.7 |  |  | 81.5 |  |  | 59.6 |  |  | 55.0 |
Total Segment Income from Operations | (3.2) |  |  |  | 12.4 |  |  | 87.5 |  |  | 73.5 |  |  | 65.2 |
Corporate and other | (19.7) |  |  |  | (54.0) |  |  | (76.3) |  |  | (50.5) |  |  | (36.4) |
Consolidated Income from Operations | $ | (22.9) |  |  |  | $ | (41.6) |  |  | $ | 11.2 |  |  | $ | 23.0 |  |  | $ | 28.8 |
Capital Expenditures |  |  |  |  |  |  |  |  |  |
Medical | $ | 3.8 |  |  |  | $ | 6.8 |  |  | $ | 14.2 |  |  | $ | 10.1 |  |  | $ | 8.0 |
Industrial | 2.0 |  |  |  | 2.7 |  |  | 12.2 |  |  | 11.4 |  |  | 10.4 |
Total operating and reportable segments | 5.8 |  |  |  | 9.5 |  |  | 26.4 |  |  | 21.5 |  |  | 18.4 |
Corporate and other | 0.3 |  |  |  | 0.3 |  |  | — |  |  | 0.4 |  |  | 0.8 |
Total Capital Expenditures | $ | 6.1 |  |  |  | $ | 9.8 |  |  | $ | 26.4 |  |  | $ | 21.9 |  |  | $ | 19.2 |
Depreciation and Amortization |  |  |  |  |  |  |  |  |  |
Medical | $ | 17.0 |  |  |  | $ | 13.3 |  |  | $ | 33.3 |  |  | $ | 15.8 |  |  | $ | 15.4 |
Industrial | 20.1 |  |  |  | 12.4 |  |  | 49.7 |  |  | 52.2 |  |  | 53.7 |
Total operating and reportable segments | 37.1 |  |  |  | 25.7 |  |  | 83.0 |  |  | 68.0 |  |  | 69.1 |
Corporate and other | 0.2 |  |  |  | 0.2 |  |  | 0.6 |  |  | 0.4 |  |  | 0.4 |
Total Depreciation and Amortization | $ | 37.3 |  |  |  | $ | 25.9 |  |  | $ | 83.6 |  |  | $ | 68.4 |  |  | $ | 69.5 |
The Company’s assets by reportable segment were not included, as this information is not reviewed by, nor otherwise provided to, the chief operating decision maker to make operating decisions or allocate resources. The following details revenues and property, plant, and equipment, net by geographic region. Revenues generated from external customers are attributed to geographic regions through sales from site locations (in millions).
| Revenues
| Successor |  |  | Predecessor
| From October 20, 2021 through December 31, 2021 |  |  | From July 1, 2021 through October 19, 2021 |  | For Year Ended June 30. 2021 |  | For Year Ended June 30. 2020 |  | For Year Ended June 30, 2019
North America |  |  |  |  |  |  |  |  |  |
Medical | $ | 45.3 |  |  |  | $ | 54.6 |  |  | $ | 138.6 |  |  | $ | 57.5 |  |  | $ | 41.0 |
Industrial | 47.6 |  |  |  | 53.4 |  |  | 199.4 |  |  | 193.3 |  |  | 188.3 |
Total North America | $ | 92.9 |  |  |  | $ | 108.0 |  |  | $ | 338.0 |  |  | $ | 250.8 |  |  | $ | 229.3 |
Europe |  |  |  |  |  |  |  |  |  |
Medical | $ | 3.9 |  |  |  | $ | 5.7 |  |  | $ | 17.1 |  |  | $ | 5.2 |  |  | $ | 1.9 |
Industrial | 55.3 |  |  |  | 52.6 |  |  | 241.5 |  |  | 206.2 |  |  | 194.9 |
Total Europe | $ | 59.2 |  |  |  | $ | 58.3 |  |  | $ | 258.6 |  |  | $ | 211.4 |  |  | $ | 196.8 |
Asia Pacific |  |  |  |  |  |  |  |  |  |
Medical | $ | — |  |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Industrial | 2.0 |  |  |  | 1.7 |  |  | 15.0 |  |  | 16.0 |  |  | 14.0 |
Total Asia Pacific | $ | 2.0 |  |  |  | $ | 1.7 |  |  | $ | 15.0 |  |  | $ | 16.0 |  |  | $ | 14.0 |
Total revenues | $ | 154.1 |  |  |  | $ | 168.0 |  |  | $ | 611.6 |  |  | $ | 478.2 |  |  | $ | 440.1 |
Revenues generated in the United States were $86.7 million from the Successor Period October 20, 2021 through December 31, 2021, and were $100.0 million, $306.3 million, $215.5 million, and $198.3 million from the Predecessor Periods from July 1, 2021 through October 19, 2021 and fiscal years ended June 30, 2021, 2020, and 2019, respectively. Revenues in France were $34.4 million from the Successor Period October 20, 2021 through December 31, 2021 and $35.1 million, $158.8 million, $134.5 million, and $128.0 million from the Predecessor Periods from July 1, 2021 through October 19, 2021 and fiscal years ended June 30, 2021, 2020, and 2019, respectively. No other country generated more than 10% of revenue individually. The following details revenues by timing of recognition (in millions):
| Revenues
| Successor |  |  | Predecessor
| From October 20, 2021 through December 31, 2021 |  |  | From July 1, 2021 through October 19, 2021 |  | For Year Ended June 30. 2021 |  | For Year Ended June 30. 2020 |  | For Year Ended June 30, 2019
Point in time | $ | 120.1 |  |  |  | $ | 123.6 |  |  | $ | 456.6 |  |  | $ | 337.3 |  |  | $ | 331.1 |
Over time | 34.0 |  |  |  | 44.4 |  |  | 155.0 |  |  | 140.9 |  |  | 109.0 |
Total revenues | $ | 154.1 |  |  |  | $ | 168.0 |  |  | $ | 611.6 |  |  | $ | 478.2 |  |  | $ | 440.1 |
The following details revenues by product category (in millions):
| Revenues
| Successor |  |  | Predecessor
| From October 20, 2021 through December 31, 2021 |  |  | From July 1, 2021 through October 19, 2021 |  | For Year Ended June 30. 2021 |  | For Year Ended June 30. 2020 |  | For Year Ended June 30, 2019
Medical segment: |  |  |  |  |  |  |  |  |  |
Medical | $ | 49.2 |  |  |  | $ | 60.3 |  |  | $ | 155.7 |  |  | $ | 62.6 |  |  | $ | 42.9 |
Industrial segment: |  |  |  |  |  |  |  |  |  |
Reactor Safety and Control Systems | 30.6 |  |  |  | 34.7 |  |  | 146.8 |  |  | 135.4 |  |  | 133.3 |
Radiological Search, Measurement, and Analysis Systems | 74.3 |  |  |  | 73.0 |  |  | 309.1 |  |  | 280.2 |  |  | 263.9 |
Total revenues | $ | 154.1 |  |  |  | $ | 168.0 |  |  | $ | 611.6 |  |  | $ | 478.2 |  |  | $ | 440.1 |
The following details property, plant, and equipment, net by geography (in millions):
| Property, Plant, and Equipment, Net
| Successor |  |  | Predecessor
| As of December 31, 2021 |  |  | As of June 30, 2021 |  | As of June 30, 2020
North America | $ | 77.1 |  |  |  | $ | 47.5 |  |  | $ | 36.5 |
Europe | 46.7 |  |  |  | 41.1 |  |  | 38.6 |
Asia Pacific | 0.2 |  |  |  | 0.2 |  |  | 0.1 |
Total | $ | 124.0 |  |  |  | $ | 88.8 |  |  | $ | 75.2 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration